SCHEMBL2835609

SCHEMBL2835609

COC/C=C/C(=O)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835611 1.00
SCHEMBL11597748 0.79 AKT1 (0.50)
SCHEMBL15750770 0.77
SCHEMBL461154 0.77
SCHEMBL10033306 0.77
SCHEMBL41826 0.77
SCHEMBL13039799 0.77
SCHEMBL1161835 0.77
SCHEMBL22660275 0.77
SCHEMBL18131527 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117412964-A Substituted heterocyclic compounds and their use 首药控股(北京)股份有限公司 2024-01-16 CN disclosed
WO-2022253309-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF 首药控股(北京)股份有限公司 2022-12-08 WO disclosed
EP-3323817-B1 ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2022-10-19 EP disclosed
WO-2022127827-A1 KRASG12C PROTEIN MUTATION INHIBITOR AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 上海维申医药有限公司 2022-06-23 WO disclosed
CN-114644631-A KRAS G12C protein mutation inhibitor, preparation method thereof, pharmaceutical composition and application thereof 上海维申医药有限公司 2022-06-21 CN disclosed
CN-109641908-B Five-membered heterocyclic [3,4-d ] pyridazinone compound, preparation method thereof, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2021-11-19 CN disclosed
US-10329277-B2 N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-06-25 US disclosed
US-20190135818-A1 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF SHANGHAI INST MATERIA MEDICA CAS (CN) 2019-05-09 US disclosed
EP-3470415-A1 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D]PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2019-04-17 EP disclosed
US-20180208581-A1 ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2018-07-26 US disclosed
WO-1999009016-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1999-02-25 WO disclosed
WO-1998043960-A1 SUBSTITUTED 3-CYANO QUINOLINES AMERICAN CYANAMID COMPANY (US) 1998-10-08 WO disclosed
US-5550161-A COMPOUNDS WHICH CHELATE IRON AND ALUMINUM IONS; TREATMENT OF VARIOUS ANEMIAS, HEMOSIDEROSIS, ALZHEIMER*S DISEASE ORAL-D (US) 1996-08-27 US disclosed
WO-1992020227-A1 SUBSTITUTED ORALLY EFFECTIVE ION CHELATORS RELATED TO DEFEROXAMINE ORAL-D (US) 1992-11-26 WO disclosed
US-5047421-A Treating trivalent metal overload conditions in humans ORAL-D (US) 1991-09-10 US disclosed
US-5015664-A Orally effective ion chelators related to deferoxamine ORAL D (US) 1991-05-14 US disclosed
US-4684482-A DEFEROXAMINE DERIVATIVES ORAL-D (L.P.) (US) 1987-08-04 US disclosed
US-4671901-A DIFEROXAMINE DERIVATIVES FOR REDUCTION OF METAL ION TUSSUE OV ERLOAD ORAL-D (US) 1987-06-09 US disclosed
EP-0171414-A1 ORALLY EFFECTIVE ION CHELATORS RELATED TO DEFEROXAMINE. ORAL D (US) 1986-02-19 EP disclosed
WO-1985003290-A1 ORALLY EFFECTIVE ION CHELATORS RELATED TO DEFEROXAMINE ORAL-D (US) 1985-08-01 WO disclosed